Company profile
Lineage Cell Therapeutics, Inc.
AMEX: LCTX · Healthcare · Biotechnology
#587 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
56CFH 40DQ 71GM 63SS 75
v0.1 · 65/100 weight · provisional
↑ listing tenure, 3-yr revenue growth · ↓ growth stability, return on equity
Methodology →Revenue TTM
$14.8M
Rev growth YoY (TTM)
+54.6%
Net income (FY)
-$63.5M
Employees
75
as of 2026-08-12
Market cap
$279.2M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.6M$14.6M2025
Net income-$63.5M-$63.5M2025
Operating income-$36.6M-$36.6M2025
Total assets$112.6M$112.6M2025
Liabilities$69.2M$69.2M2025
Equity$44.5M$44.5M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenues100%
By geography
Non-US100%
The read
What is Lineage Cell Therapeutics, Inc.’s revenue?
Lineage Cell Therapeutics, Inc. booked $14.6M in FY2025 revenue, growing 53% year over year — faster than most Healthcare companies we track, at a -436.5% net margin.
Peers · Healthcare
Relay Therapeutics, Inc.57CAllurion Technologies Inc.26DVSee Health, Inc.35DSunniva Inc.——Urologix, Inc.——Opus Genetics, Inc.39DNeighbors
San Diego →Key facts
CEOBrian Culley
SectorHealthcare
IndustryBiotechnology
HeadquartersCarlsbad, CA
ExchangeAMEX: LCTX
Employees75
IPO date1992-03-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.